Answers are grounded in this paper and cite their sources.
The search for a therapeutic ‘magic bullet’ for the management of malignant disease has a long history. Despite past failures, many clinicians have remained optimistic that once sufficient insight has been gained into the pathogenesis of the malignant process it may be possible to specifically target transformed cells and so open up new possibilities for therapy. The latest candidate for the title of ‘magic bullet’, and probably the best to date, is antisense (AS) therapeutics. Sequences of RNA or DNA which are complementary to target sequences within a cell appear to be capable of specifically down-regulating the products of that target gene. When applied to oncogenes, such a strategy might allow precise modulation of those genes believed to be responsible for the process of malignant transformation, leading to death of the malignant cell or altering its biology in such a way as to render it harmless. Here we review briefly the background to AS therapeutics and then examine the results available to date as they relate to haematological malignancies.
No takes yet. Share an insight, caveat, or question.
Mark A. Kirkland (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: